REGENXBIO completed enrollment in pivotal gene therapy trial;  still enrolling the confirmatory trial ages 1 year and above

- Posted in General, Research

Updated 10/31/2015:
Letter to the community:

Community letter – Affinity Duchenne pivotal ends Oct2025 vFDownload

October 30, 2025
REGENXBIO announced that they have completed enrollment in the Phase 1/2 portion of their RGX-202 microdystrophin gene therapy trial, with topline data expected in Q2 2026.  They are continuing to enroll participants aged 1 year and above in the confirmatory trial, and have initiated manufacturing of commercial supply of drug.

Read more here: https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-completion-pivotal-enrollment-and-initiates

AFFINITY DUCHENNE Enrollment Completion PR_FinalDownload

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate